Loading clinical trials...

NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC | Clinical Trials | Clareo Health

RECRUITINGEARLY_PHASE1

NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC

ICG-Cisplatin Self-Assembled Nanoprobes for Near-Infrared-Il Fluorescence Imaging-Guided Liver Resection

NCT07295262•West China Hospital

Summary

This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age 18-75 years.
•2. First diagnosis of Hepatocellular Carcinoma (HCC) (non-recurrent).
•3. Single tumor with diameter ≤ 5 cm.
•4. Assessed as resectable by more than 2 senior liver surgeons (experience \>10 years, \>500 hepatectomies).
•5. No distant metastasis on preoperative chest CT and abdominal contrast-enhanced CT.
•6. Child-Pugh Class A liver function.
•7. Patient or legal guardian able to understand the study and sign informed consent.

Exclusion Criteria

•1. Postoperative pathology confirms cholangiocarcinoma, sarcomatoid HCC, combined HCC-ICC, or fibrolamellar carcinoma.
•2. Presence of portal vein, hepatic vein, or bile duct tumor thrombus.
•3. History of other malignancies (except cured carcinoma in situ of cervix, basal cell carcinoma, or squamous cell skin carcinoma).
•4. Evidence of residual lesion, recurrence, or metastasis during preoperative assessment; or postoperative pathology confirming lymph node metastasis or positive margins.
•5. Moderate to severe ascites requiring therapeutic paracentesis/drainage, or Child-Pugh score \> 7 (except for small amount of ascites on imaging without clinical symptoms).
•6. Uncontrolled or moderate/large amount of pleural effusion or pericardial effusion.
•7. Severe cardiac, pulmonary, or renal dysfunction.
•8. Ruptured HCC requiring emergency surgery.
•9. Patient or family unable to understand the study conditions and objectives.

Locations (1)

West China Hospital

Chengdu, Sichuan, China

Key Dates

Start Date

January 1, 2026

Primary Completion Date

July 1, 2028

Completion Date

December 1, 2028

Last Updated

December 19, 2025

Enrollment

ESTIMATED participants

Conditions

Liver Cancer, Adult

Interventions

ICG-Cisplatin Nanoprobe (NIR-II NanoM)

DRUG

Fluorescence-guided Hepatectomy

PROCEDURE

Contacts

Jiwei Huang Professor

CONTACT

18980606725 huangjiwei@wchscu.cn

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

NCT04567615

Hepatocellular CarcinomaHepatoma+3 more

View study

NOT_YET_RECRUITING

The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/Contrast-enhanced MRI in Malignant Liver Lesions

NCT07055048

Liver Cancer, Adult

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions